CIBC Private Wealth Group
URGN icon

CIBC Private Wealth Group’s UroGen Pharma URGN Stock Holding History

CIBC Private Wealth Group’s Portfolio URGN Stock Details URGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$13.5K Buy
575
+66
+13% +$1.43K ﹤0.01% 2314
2025
Q3 		$10.2K Hold
509
– – ﹤0.01% 2379
2025
Q2 		$6.97K Hold
509
– – ﹤0.01% 2371
2025
Q1 		$4.92K Hold
509
– – ﹤0.01% 2461
2024
Q4 		$5.62K Hold
509
– – ﹤0.01% 2439
2024
Q3 		$6.46K Hold
509
– – ﹤0.01% 2528
2024
Q2 		$8.2K Hold
509
– – ﹤0.01% 2359
2024
Q1 		$7.23K Buy
+509
New +$8.32K ﹤0.01% 2400

Other funds holding URGN

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
JFG
Jefferies Financial Group New York $15.2B AUM 55.75% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $962M AUM 524.64% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
SG Americas Securities
SG Americas Securities New York $179B AUM 65.34% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $25.6B AUM 50.04% 1-Year Est. Return

CIBC Private Wealth Group's URGN Position: Q4 2025 in Review

CIBC Private Wealth Group increased its UroGen Pharma (URGN) stake by 13% in Q4 2025, buying an estimated $1.43K and bringing the position to 575 shares worth $13.5K. The position accounts for ﹤0.01% of the portfolio, ranked #2314.

CIBC Private Wealth Group first reported a position in URGN in Q1 2024 and has held it in 8 quarters since. 167 funds tracked by Wall St. Rank hold URGN as of Q4 2025.

  • CIBC Private Wealth Group held 575 shares of UroGen Pharma worth $13.5K as of Q4 2025.
  • CIBC Private Wealth Group bought 66 UroGen Pharma shares in Q4 2025, an estimated $1.43K.
  • UroGen Pharma made up ﹤0.01% of CIBC Private Wealth Group's portfolio in Q4 2025, its #2314 holding.
  • CIBC Private Wealth Group first reported a position in UroGen Pharma in Q1 2024 and has held it in 8 quarters since.
  • 167 funds tracked by Wall St. Rank held UroGen Pharma as of Q4 2025.

Based on CIBC Private Wealth Group's 13F filing for Q4 2025, filed 12 Feb 2026.